New Triple-Action Drug Promises Major Weight Loss

A new generation of weight-loss medication, informally termed 'GLP-3,' is emerging with potent effects that surpass existing GLP-1 treatments. Retatrutide, a triple-agonist developed by Eli Lilly, targets GLP-1, GIP, and glucagon receptors. This multifaceted approach has yielded significant results in clinical trials. For example, a phase 3 trial concluded in December, showing participants with obesity and knee arthritis lost an average of 71.8 lbs (28.7%) over 68 weeks.

Beyond its impact on weight, retatrutide demonstrates substantial benefits for related health issues. The same trial reported a 75.8% average reduction in knee arthritis pain scores, indicating significant improvements in comfort and mobility. These findings suggest that retatrutide could offer a dual benefit for individuals struggling with both obesity and associated joint pain and dysfunction.

With seven additional phase 3 trials expected to conclude in 2026, retatrutide could potentially receive FDA approval in 2027, marking a new milestone in obesity treatment. While gastrointestinal issues are common side effects, similar to GLP-1 drugs, its broader metabolic benefits may extend to conditions like type 2 diabetes and cardiovascular risk reduction.